Get the Stockscreener App
1.04
0.97%
0.01
Intercure Ltd stock is traded at $1.04, with a volume of 84,599.
It is up +0.97% in the last 24 hours and up +14.85% over the past month.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
See More
Previous Close:
$1.03
Open:
$1.0263
24h Volume:
84,599
Relative Volume:
1.60
Market Cap:
$59.44M
Revenue:
$117.93M
Net Income/Loss:
$5.00M
P/E Ratio:
7.9148
EPS:
0.1314
Net Cash Flow:
$-12.91M
1W Performance:
+11.98%
1M Performance:
+14.85%
6M Performance:
-7.56%
1Y Performance:
-30.20%
1-Day Range:
$1.01
$1.07
1-Week Range:
$0.9398
$1.16
52-Week Range:
$0.68
$1.7698
Intercure Ltd Stock (INCR) Company Profile
Compare INCR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.04 | 59.44M | 117.93M | 5.00M | -12.91M | 0.1314 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.21 | 38.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.09 | 31.90B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
542.66 | 23.03B | 3.17B | 1.29B | 1.01B | 27.09 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-22 | Upgrade | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Stock (INCR) Latest News
InterCure Ltd. Actuals & Estimates (TASE:INCR) - TradingView
Price to earnings forward of InterCure Ltd. – TASE:INCR - TradingView
InterCure Ltd. Actuals & Estimates (BOATS:INCR) - TradingView
Price to sales forward of InterCure Ltd. – TASE:INCR - TradingView
InterCure Ltd (INCR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
InterCure secures $7.4M funding commitment, may rise to $18.6M - Investing.com UK
InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors. - marketscreener.com
InterCure Secures NIS 22 Million Private Placement to Fund Global Medical Cannabis Expansion - TipRanks
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds - markets.businessinsider.com
InterCure secures $7.4M funding commitment, may rise to $18.6M By Investing.com - Investing.com South Africa
InterCure (NASDAQ: INCR) lines up NIS 22–54 million private placement funding - Stock Titan
InterCure raises NIS 22M, with room to reach NIS 54M - Stock Titan
InterCure Ltd (INCR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
InterCure Ltd (INCR) Institutional Confidence - TradingKey
InterCure Ltd (INCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
InterCure Ltd (INCR) Valuation: PE, PB & Fair Value Analysis - TradingKey
InterCure Ltd (INCR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
InterCure Ltd (INCR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
InterCure Ltd (INCR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
InterCure Ltd (INCR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
InterCure Advances Global Push With Botanico Acquisition Tranche and U.S. Strategy Review - The Globe and Mail
InterCure completes Botanico acquisition and expands into U.S. medical cannabis - MMJDaily
InterCure Initiates Review of US Medical Cannabis Opportunities Following Federal Rescheduling - Cannabis Business Times
InterCure completes first tranche of Botanico acquisition By Investing.com - Investing.com South Africa
InterCure Ltd. Completes First Tranche of Botanico Acquisition to Enhance International Medical Cannabis Platform - Moomoo
InterCure (NASDAQ: INCR) advances Botanico deal and eyes U.S. medical cannabis - Stock Titan
InterCure Initiates Strategic Review of U.S. Medical - GlobeNewswire
U.S. cannabis shift prompts InterCure rethink and new launches in Germany - Stock Titan
Intercure Ltd. (INCR) Holds Near Support as Modest Gains Signal Stabilization AttemptRevenue Weighted - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates by Nearly 29%, Yet Stock Sheds ValueSegment Revenue Breakdown - newsline.com
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.7%, Driving Stock HigherPositive Surprise Momentum - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates, Stock Declines Amid Broader Market HeadwindsAnalyst Coverage Count - newsline.com
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Beat Drives 12.15% Stock SurgeEnergy Earnings Report - newsline.com
INCR Q2 2023 Earnings: EPS Surpasses Estimates by 28.68%Debt Analysis Report - The Legal Advocate
Intercure Ltd. (INCR) Q2 2023 Earnings: EPS Surges Past Estimates, Stock RalliesSurprise Factor Analysis - The Legal Advocate
Intercure Ltd. Shares Surge Over 15% as Cannabis Sector Sees Renewed InterestThrowback Trade - newsline.com
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Profitability StrengthensProfit Warning Alert - The Legal Advocate
Intercure Ltd. (INCR) Rallies 5.57% as It Approaches Key Resistance LevelRSI Oversold Picks - The Legal Advocate
INCR Q2 2023 Earnings: Strong EPS Beat Highlights Operational EfficiencyEarnings Analysis - thelegaladvocate.com
Intercure Ltd. (INCR) Rallies 4.8%: Testing Key Resistance at $0.97Risk Reward Setups - newsline.com
INCR Q2 2023 Earnings: EPS Beat Surprises by 28.7% Despite Revenue UncertaintyAnalyst Drop Coverage - Město Břeclav
INCR Q2 2023 Earnings: EPS Surges Past Estimates as Company Delivers Strong Operational ResultsEarnings Trend Analysis - Newser
INCR Q2 2023 Earnings: EPS Surprises 28.68% Above Estimates Despite Negative Stock ReactionSocial Signal Watchlist - Newser
INCR (Intercure) beats Q2 estimates by 28% but shares fall 4% despite earnings surprise.AI Stock Signals - newser.com
How Intercure (INCR) performance reflects its true potential (Smart Money Flows) 2026-05-05Real Trader Insights - newser.com
InterCure Posts 2025 Revenue Growth, Positive Cash Flow as Recovery and Expansion Accelerate - The Globe and Mail
InterCure (NASDAQ: INCR) grows 2025 revenue to NIS 270M with positive cash flow - Stock Titan
InterCure Ltd. Reports NIS 270 Million Revenue and Positive Cash Flow for 2025 Amid Recovery Efforts - Quiver Quantitative
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow - Weekly Voice
Intercure LTD (INCR) Releases Q4 2025 Earnings: Revenue Up 43.8% but Company Remains Unprofitable - Quiver Quantitative
InterCure (INCR) 2025 20-F outlines licensing, war and market risks - Stock Titan
Intercure Ltd Stock (INCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.26%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):